Reply to Matters Arising: Is congenital anosmia protective for Parkinson's disease triggered by pathogenic entrance through the nose?

被引：0
|
作者：
Arshamian, Artin [1 ]
Iravani, Behzad [1 ,2 ]
Lundstrom, Johan N. [1 ,3 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[2] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA USA
[3] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA
来源：
NPJ PARKINSONS DISEASE | 2023年 / 9卷 / 01期
基金：
瑞典研究理事会;
关键词：
D O I：
10.1038/s41531-023-00539-4
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页数：2
相关论文
共 29 条
  • [1] Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?
    Artin Arshamian
    Behzad Iravani
    Johan N. Lundström
    npj Parkinson's Disease, 9
  • [2] Matters Arising: Is congenital anosmia protective for Parkinson's disease triggered by pathogenic entrance through the nose?
    Fjaeldstad, Alexander Wieck
    NPJ PARKINSONS DISEASE, 2023, 9 (01)
  • [3] Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?
    Alexander Wieck Fjaeldstad
    npj Parkinson's Disease, 9
  • [4] Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?
    Artin Arshamian
    Behzad Iravani
    Johan N. Lundström
    npj Parkinson's Disease, 8
  • [5] Is congenital anosmia protective for Parkinson's disease triggered by pathogenic entrance through the nose?
    Arshamian, Artin
    Iravani, Behzad
    Lundstrom, Johan N.
    NPJ PARKINSONS DISEASE, 2022, 8 (01)
  • [6] Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease
    Price, Diana L.
    Khan, Asma
    Angers, Rachel
    Cardenas, Alvaro
    Prato, Maria Key
    Bani, Massimo
    Bonhaus, Douglas W.
    Citron, Martin
    Biere, Anja-Leona
    NPJ PARKINSONS DISEASE, 2024, 10 (01)
  • [7] Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
    Diana L. Price
    Asma Khan
    Rachel Angers
    Alvaro Cardenas
    Maria Key Prato
    Massimo Bani
    Douglas W. Bonhaus
    Martin Citron
    Anja-Leona Biere
    npj Parkinson's Disease, 10
  • [8] Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease
    Steiner, Michel Alexander
    NPJ PARKINSONS DISEASE, 2024, 10 (01)
  • [9] Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
    Michel Alexander Steiner
    npj Parkinson's Disease, 10
  • [10] Protective effect of phenylpropionamides in the seed of Cannabis Sativa L. on Parkinson's disease through autophagy
    Jiang, Yi -kai
    Li, Meng-meng
    Wang, Si-yi
    Hao, Zhi-chao
    Meng, Xin
    Kuang, Hai-xue
    Yang, Bing-you
    Liu, Yan
    FITOTERAPIA, 2024, 175
123